SABCS 2025 – Roche mounts its early breast cancer challenge
Giredestrant’s adjuvant benefit looks similar to that of Kisqali and Verzenio.
ASH 2025 – Terns wins
The company might have blown Enliven out of the water.
ASH 2025 – Lilly claims Jaypirca is best
Studies presented at ASH show this to be true only up to a point.
ASH 2025 – J&J’s multiple myeloma juggling act
Tecvayli plus Darzalex could challenge Carvykti in the push for a functional cure.
ASH 2025 – Regeneron’s Lynozyfic shows front-line promise
Linker-MM4 data raise more questions about sequencing of therapies for multiple myeloma.
ASH 2025 – Adcetris good, follow-ons not so much
Pfizer reveals the discontinuation of PF-08046044.
ASH 2025 – Gilead spills the beans on “fast” Car-T
It’s less about being fast, more about producing a better product.
